<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911002-0111</DOCNO><DOCID>911002-0111.</DOCID><HL>   Technology Brief -- Pharmaceutical Resources Inc.:   Par Unit Agrees in Principle   To Settle Class-Action Suits</HL><DATE>09/30/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C13</SO><CO>   PRX</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>SHAREHOLDER RIGHTS PLANS (SRP)</NS><RE>NORTH AMERICA (NME)NEW YORK (NY)UNITED STATES (US)</RE><LP>   Pharmaceutical Resources Inc. said its embattled ParPharmaceutical unit reached an agreement in principle tosettle all class actions against it, its Quad subsidiary andcertain officers.   The settlement calls for Pharmaceutical Resources, SpringValley, N.Y., to issue 2,000 nonvoting shares of convertiblepreferred stock and 375,000 shares of common stock, to bedistributed proportionately among members of the class.</LP><TEXT>   &quot;This settlement resolves one of the major issues that hadbeen burdening the future of the company,&quot; said Kenneth I.Sawyer, Pharmaceutical Resources president. &quot;Management hasworked hard in this settlement to preserve the company'sworking capital.&quot;   In January 1990, Par and its Quad unit, both makers ofgeneric drugs, were fined for illegal payments made by twoformer officers to a Food and Drug Administration official,and Quad has been barred from doing business with the federalgovernment until Aug. 31, 1992. The lawsuits were filed as aresult of the FDA action.   The settlement is subject to approval of the U.S. DistrictCourt in New York and Par's board and shareholders.   ---   Corrections andamp; Amplifications                                                                                                          PHARMACEUTICAL RESOURCES Inc. will issue two millionnonvoting convertible preferred shares as part of anagreement to settle all class and shareholder actions againstits Par Pharmaceutical Inc. and Quad Pharmaceuticals Inc.units. The number of preferred shares was misstated inMonday's edition.   (WSJ Oct. 2, 1991)</TEXT></DOC>